Loading clinical trials...
Loading clinical trials...
A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)
Conditions
Interventions
Tafamidis
Tafamidis
+1 more
Locations
80
United States
The Kirklin Clinic
Birmingham, Alabama, United States
UAB Hospital Department of Pharmacy IDS
Birmingham, Alabama, United States
University Hospital, University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic Arizona - Mayo Clinic Speciality Building
Phoenix, Arizona, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
Mayo Clinic Arizona - Mayo Clinic Building
Scottsdale, Arizona, United States
Start Date
December 9, 2013
Primary Completion Date
February 7, 2018
Completion Date
February 7, 2018
Last Updated
April 24, 2019
NCT07196839
NCT04108091
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions